{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"Disease responses for HR MDS or CMML are based on the International Working Group (IWG) Response Criteria for MDS. CR for HR MDS or CMML is defined as \\<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and \\>=11 g/dL Hgb, \\>=100\\*10\\^9/L platelets (pl), \\>=1.0\\*10\\^9/L neutrophils and 0% blasts in peripheral blood. Marrow CR: Bone marrow: \\<=5% myeloblasts and decrease by \\>=50% over pretreatment.","groups":[{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG001","title":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment.","reportingStatus":"POSTED","timeFrame":"From randomization until CR or marrow CR (up to approximately 42 months)","title":"Number of Participants With CR and Marrow CR","type":"SECONDARY","unitOfMeasure":"Participants"}